Neopharma

Started in 2003, the first manufacturing facilities of Neopharma were planned on an investment outlay of US$25 million. Spread over an area of 100,000m2, the plant encompasses two independent production blocks – one dedicated for the manufacture of general products and the other, an exclusive centre for manufacturing betalactam products. In addition to the above, the plant has an exclusive area for the formulations Research and Development block. Neopharma lays strong emphasis on research towards development of processes and products that are patent non-infringing – a route that can propel the company towards attaining leading position in the Middle East Region. Neopharma has a vibrant R & D centre that collaborates to both in-house and collaborative manufacturer’s needs. This is housed along with the Quality control testing labs, Quality Assurance, Regulatory and Administration departments.

Unlike many pharmaceutical plants that were set up earlier, the Neopharma facility is built on the concept of modular manufacturing. This specialised unidirectional flow of work process ensures that there is no risk of cross contamination and the final product meets the highest quality standards. Besides the factory follows global benchmarks in manufacturing technology and efficient control methods that ensure the end products meet the final specifications.

The internal layout of the plant is designed to independently manufacture and pack a variety of pharmaceutical dosage forms including tablets, capsules, and dry powder for reconstitution, syrups, suspensions, solutions and sachets. Neopharma employs the latest automated PLC controlled machines for the entire manufacturing process.

The equipment is procured from the world’s best manufacturers such as granulators from M/s Diosna, Germany, Tablet presses and auto-coaters from M/s Manesty – UK, and Liquid manufacturing plant form M/s Diessel, Germany to name a few.